Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

Trial Failure:
Roche's TIGIT drug candidate, tiragolumab, failed to meet the primary endpoint of overall survival (OS) in the Phase 3 SKYSCRAPER-01 trial for lung cancer patients[2][4].

Combination Therapy:
The trial evaluated tiragolumab in combination with Tecentriq (atezolizumab) in patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC)[2].

Previous Failures:
This is not the first setback for tiragolumab; it previously failed to show a statistically significant progression-free survival (PFS) benefit in SKYSCRAPER-01 and missed both PFS and OS endpoints in the SKYSCRAPER-02 trial for small-cell lung cancer[2].

Comparison to Keytruda:
In another trial, SKYSCRAPER-06, tiragolumab combined with Tecentriq failed to outperform Merck & Co.’s Keytruda plus chemotherapy in non-squamous NSCLC patients[1].

Future Plans:
Roche will review its study programs to determine if adjustments are necessary, with additional data from Phase III studies across different settings or tumor types anticipated next year[2].